Roper Martin, CEO of both MGP Ingredients (MGPI) and Vita Coco Company (COCO), has maintained a consistently one-sided posture in his SEC Form 4 filings over the past year: he has sold, but never bought, shares in the open market. Across 56 total transactions spanning two companies, Martin has executed zero open-market purchases while recording $16.26 million in sales, all of it in COCO. His only acquisitions—$3.31 million in total—came through option exercises (code M) and restricted stock grants (code A), which are compensation mechanics rather than discretionary investments.
The selling pattern in COCO has been particularly dense and methodical. Between April 7 and April 29, 2026, Martin filed 11 separate open-market sales (code S) totaling roughly $12.5 million, with individual transactions ranging from $225,246 to $1.28 million. Each sale was paired with an option exercise of equal share count, a structure that suggests systematic liquidation of vested awards rather than opportunistic timing. The largest single-day sale occurred on April 28 at $1.28 million, and the cluster of near-identical $1.25 million sales across multiple days points to a pre-arranged 10b5-1 plan or similar scheduled disposition.
In contrast, Martin's MGPI activity has been entirely passive. His recent filings there show only code A grants—$38,747 on July 2, 2026, and $38,734 on April 2—with no sales or exercises. The asymmetry between the two tickers is stark: all selling pressure is concentrated in COCO, while MGPI holdings remain untouched. Over the trailing 12 months, Martin's net cash position from these filings is negative $16.26 million, entirely driven by COCO dispositions, with no corresponding open-market buying in either company to offset the outflow.
AI-assisted summary